| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
797 |
775 |
$79K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
251 |
240 |
$32K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
134 |
130 |
$20K |
| 87428 |
|
138 |
132 |
$2K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
77 |
70 |
$1K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
29 |
29 |
$923.60 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
297 |
275 |
$897.81 |
| 82550 |
|
114 |
107 |
$424.23 |
| 80051 |
|
100 |
94 |
$371.00 |
| 82565 |
|
100 |
94 |
$339.75 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
26 |
25 |
$286.22 |
| 84520 |
|
98 |
92 |
$272.00 |
| 80053 |
Comprehensive metabolic panel |
41 |
39 |
$263.04 |
| 82947 |
|
116 |
105 |
$216.00 |
| 81003 |
|
98 |
92 |
$145.70 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
29 |
29 |
$125.00 |
| 81025 |
|
43 |
38 |
$74.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
26 |
25 |
$24.00 |